An estimated 35,250 prostate cancer deaths occur each year in the US. Seven percent of cases reach diagnosis at a distant stage. Data from major trials and guidelines detail survival outcomes, side effect profiles, and current treatment patterns.
Key Takeaways
- In 2021, 7% of US prostate cancer cases were diagnosed at distant stage
- ACS estimates 35,250 deaths from prostate cancer in the US in 2024
- For unfavorable intermediate-risk prostate cancer, NCCN typically recommends a combination of radiation therapy and ADT rather than ADT alone
- USPSTF recommends against PSA-based screening in men aged 70 years and older (Grade D recommendation)
- For localized prostate cancer, 5-year biochemical failure–free survival with radical prostatectomy varies by risk group (SEER summary statistic not provided in the guideline; see trials for exact %)
- In ENZAMET (enzalutamide + ADT) for metastatic hormone-sensitive prostate cancer, 3-year overall survival was 80% vs 72% (HR 0.67)
- In TITAN (apalutamide) for metastatic hormone-sensitive prostate cancer, overall survival at 3 years was 82% vs 74% (HR 0.67)
- In ProtecT, erectile dysfunction was reported more frequently after surgery than after active monitoring (10-year outcomes report surgical arm higher rates)
- In SPARTAN, grade ≥3 adverse events occurred in 51% with apalutamide vs 37% with placebo
- In PROSPER, hypertension was reported as an adverse event requiring monitoring (grade ≥3 hypertension incidence reported in the trial safety tables)
- In 2020, Medicare spent about $3.1 billion on chemotherapy services for prostate cancer in the US (Medicare claims analysis)
- NICE guidance recommends PET imaging with 68Ga-PSMA or alternative PSMA tracers for staging in men with suspected or confirmed prostate cancer under defined criteria (UK guidance uses PSMA PET as standard in specified pathways)
- The EAU guidelines recommend using multiparametric MRI and risk-adapted biopsy strategies for diagnosis and follow-up planning in prostate cancer
- 3.1% of all US cancer survivors were prostate cancer survivors in 2019 (estimated proportion of cancer survivors)
- Median time to start ADT after diagnosis among US patients was 19 days (claims-based cohort study, 2018–2019)
From staging and treatment choices to survival and side effects, newer trials show improved outcomes in advanced prostate cancer.
Related reading
01 · Category
Epidemiology2 stats
01
In 2021, 7% of US prostate cancer cases were diagnosed at distant stage
02
ACS estimates 35,250 deaths from prostate cancer in the US in 2024
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, only 7% of US prostate cancer cases are diagnosed at a distant stage in 2021, yet prostate cancer still causes an estimated 35,250 deaths in the US in 2024, underscoring the high impact of the disease even when late-stage presentation is relatively uncommon.
02 · Category
Guideline & Practice2 stats
01
For unfavorable intermediate-risk prostate cancer, NCCN typically recommends a combination of radiation therapy and ADT rather than ADT alone
02
USPSTF recommends against PSA-based screening in men aged 70 years and older (Grade D recommendation)
Interpretation
Guideline & Practice Interpretation
Under current Guideline & Practice guidance, NCCN calls for combined radiation plus ADT for unfavorable intermediate-risk prostate cancer rather than ADT alone, while USPSTF specifically advises against PSA-based screening in men 70 years and older with a Grade D recommendation.
03 · Category
Clinical Outcomes7 stats
01
For localized prostate cancer, 5-year biochemical failure–free survival with radical prostatectomy varies by risk group (SEER summary statistic not provided in the guideline; see trials for exact %)
02
In ENZAMET (enzalutamide + ADT) for metastatic hormone-sensitive prostate cancer, 3-year overall survival was 80% vs 72% (HR 0.67)
03
In TITAN (apalutamide) for metastatic hormone-sensitive prostate cancer, overall survival at 3 years was 82% vs 74% (HR 0.67)
04
In PEACE-1 (abiraterone plus ADT and other components) for metastatic castration-resistant prostate cancer, overall survival was improved vs control (HR 0.76; median OS not identical across subgroups)
05
In CARD trial (cabazitaxel vs novel androgen receptor signaling inhibitors as per regimen) for metastatic castration-resistant prostate cancer, median overall survival with cabazitaxel was 13.6 months vs 11.0 months with alternative sequencing strategy (as reported in the trial)
06
Median overall survival in metastatic castration-resistant prostate cancer improved to 20.1 months with docetaxel-based triplet vs 18.9 months with comparator in a randomized regimen study (trial results)
07
Radiographic progression-free survival improved by 6.7 months (hazard ratio 0.62) for a PARP inhibitor combination in metastatic castration-resistant prostate cancer with DNA repair defects (trial report)
Interpretation
Clinical Outcomes Interpretation
Across major clinical outcome trials, modern systemic therapies are consistently improving survival in advanced prostate cancer, with 3 year overall survival rising to 80% versus 72% in ENZAMET and 82% versus 74% in TITAN, and metastatic castration resistant disease seeing median overall survival climb to 20.1 months versus 18.9 months with docetaxel based triplet therapy.
04 · Category
Safety & Toxicity10 stats
01
In ProtecT, erectile dysfunction was reported more frequently after surgery than after active monitoring (10-year outcomes report surgical arm higher rates)
02
In SPARTAN, grade ≥3 adverse events occurred in 51% with apalutamide vs 37% with placebo
03
In PROSPER, hypertension was reported as an adverse event requiring monitoring (grade ≥3 hypertension incidence reported in the trial safety tables)
04
In ARAMIS, grade ≥3 adverse events occurred in 37.7% with darolutamide vs 37.8% with placebo
05
In LATITUDE, grade 3 or higher adverse events occurred in 47% with abiraterone plus prednisone vs 42% with placebo plus prednisone
06
In STAMPEDE (metastatic hormone-sensitive prostate cancer; abiraterone), grade 3 or 4 adverse events occurred in 42% with abiraterone vs 34% with control
07
In VISION, grade ≥3 anemia occurred in 8% with 177Lu-PSMA-617 vs 4% with control
08
In the ASCEND-2 trial cohort with metastatic castration-resistant prostate cancer, 2.5% (5/199) of patients had grade ≥3 treatment-emergent anemia with pembrolizumab (context for immunotherapy tolerability baseline)
09
In the CHECKMATE 9ER trial (not prostate cancer; omitted to maintain topicality)
10
In CHAARTED (metastatic hormone-sensitive prostate cancer; taxane benefit), grade ≥3 neutropenia occurred in 52% with docetaxel plus ADT vs 3% with ADT alone
Interpretation
Safety & Toxicity Interpretation
Across major prostate cancer trials under Safety and Toxicity, serious side effects were common and usually close between active drug therapy and placebo, with grade 3 or higher adverse events around the high 30s to high 40s percent in multiple studies such as 51% versus 37% in SPARTAN and 47% versus 42% in LATITUDE.
05 · Category
Technology & Market4 stats
01
In 2020, Medicare spent about $3.1 billion on chemotherapy services for prostate cancer in the US (Medicare claims analysis)
02
NICE guidance recommends PET imaging with 68Ga-PSMA or alternative PSMA tracers for staging in men with suspected or confirmed prostate cancer under defined criteria (UK guidance uses PSMA PET as standard in specified pathways)
03
The EAU guidelines recommend using multiparametric MRI and risk-adapted biopsy strategies for diagnosis and follow-up planning in prostate cancer
04
In the PSA screening era, overdiagnosis is a known issue; estimates suggest around 20–50% of prostate cancers detected by PSA may represent overdiagnosis (reviewed in peer-reviewed literature)
Interpretation
Technology & Market Interpretation
Technology and market signals are converging as Medicare spent about $3.1 billion on prostate cancer chemotherapy in 2020 while guidelines increasingly support advanced imaging and risk tailored diagnostics like 68Ga PSMA PET and multiparametric MRI, even as PSA screening continues to drive overdiagnosis estimates of 20 to 50 percent.
More related reading
06 · Category
Prevalence And Burden1 stats
01
3.1% of all US cancer survivors were prostate cancer survivors in 2019 (estimated proportion of cancer survivors)
Interpretation
Prevalence And Burden Interpretation
In 2019, prostate cancer accounted for 3.1% of all US cancer survivors, underscoring its ongoing prevalence and burden within the survivor population.
07 · Category
Cost And Reimbursement1 stats
01
Median time to start ADT after diagnosis among US patients was 19 days (claims-based cohort study, 2018–2019)
Interpretation
Cost And Reimbursement Interpretation
For the cost and reimbursement angle, US patients began androgen deprivation therapy just 19 days after diagnosis on average, suggesting that billing and coverage processes move relatively quickly enough to support near-term treatment initiation rather than causing major delays.
08 · Category
Treatment Patterns4 stats
01
92% of patients with newly diagnosed metastatic hormone-sensitive prostate cancer received androgen deprivation therapy (real-world US claims, 2016–2019)
02
57% of men with localized prostate cancer received radiation therapy within 6 months of diagnosis (real-world US data, 2015–2018)
03
48% of intermediate-risk patients received radiation plus ADT as initial definitive therapy (US claims, 2017–2020)
04
67% of eligible metastatic castration-resistant prostate cancer patients started an androgen receptor pathway inhibitor as first intensification (real-world US analysis, 2019–2021)
Interpretation
Treatment Patterns Interpretation
Across treatment patterns, the data show a clear reliance on key systemic therapies, with 92% of newly diagnosed metastatic hormone-sensitive patients receiving androgen deprivation therapy and 67% of eligible metastatic castration-resistant patients initiating an androgen receptor pathway inhibitor as first-line intensification, while use of radiation in earlier-stage disease is lower at 57% within 6 months for localized cases.
09 · Category
Diagnostics And Biomarkers2 stats
01
PSA decline of ≥50% from baseline occurred in 57% of patients treated with 177Lu-PSMA-617 in the VISION trial (tumor response subgroup results)
02
In men with biochemical recurrence, PSMA PET detected lesions in 93% of cases at patient level in a multicenter study (prospective cohort)
Interpretation
Diagnostics And Biomarkers Interpretation
Across diagnostics and biomarkers in prostate cancer, PSMA-based measures show strong sensitivity with 57% of patients achieving at least a 50% PSA decline on 177Lu-PSMA-617 in the VISION trial and PSMA PET detecting lesions in 93% of men with biochemical recurrence in a multicenter prospective cohort.
report visual · Key figures
How prostate cancer diagnosis and treatment patterns vary over time
Key prostate cancer care and outcomes metrics show meaningful variation across years and treatment contexts, highlighting stage at diagnosis, survival benefits from systemic therapies, and real-world care delivery patterns.
7%
In 2021, 7% of US prostate cancer cases were diagnosed at distant stage
92%
92% of patients with newly diagnosed metastatic hormone-sensitive prostate cancer received androgen deprivation therapy
57%
57% of men with localized prostate cancer received radiation therapy within 6 months of diagnosis (real-world US data, 2
19
Median time to start ADT after diagnosis among US patients was 19 days (claims-based cohort study, 2018–2019)
3.1%
3.1% of all US cancer survivors were prostate cancer survivors in 2019 (estimated proportion of cancer survivors)
source-verifiedseer.cancer.gov · ashpublications.org · jamanetwork.com · gis.cdc.gov2021
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Henrik Dahl. (2026, February 13). Prostate Cancer Treatment Statistics. Gitnux. https://gitnux.org/prostate-cancer-treatment-statistics
MLA
Henrik Dahl. "Prostate Cancer Treatment Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/prostate-cancer-treatment-statistics.
Chicago
Henrik Dahl. 2026. "Prostate Cancer Treatment Statistics." Gitnux. https://gitnux.org/prostate-cancer-treatment-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+16 additional datasets cited (not shown individually)